The Five Steps to Success in Managing Tardive Dyskinesia

This activity is designed for general, pediatric and geriatric psychiatrists, neurologists, nurse practitioners, physician assistants, nurses, psychologists, social workers, other mental health professionals and primary care clinicians interested in treating patients tardive dyskinesia or Parkinson’s Disease.

Activity Information

Original Release Date: October 31, 2018
Expiration Date: October 31, 2019
Estimated Time to Complete Activity: 1.0 hour

 

Program Overview

Tardive dyskinesia (TD) consists of involuntary movements of the tongue, lips, face, trunk, and extremities. It can be observed in patients who have received long-term treatment with dopamine receptor blocking agents such as antipsychotic agents. TD is associated with significant functional impairment and can be socially stigmatizing. It is usually irreversible. New treatment approaches to persistent TD are available, as approved by the US FDA for this purpose.

Learning Objectives

As a result of participating in this activity, participants should be able to:

  • Describe how to diagnose and assess TD using the Abnormal Involuntary Movement Scale
  • List measures that should be taken to prevent TD in patients with schizophrenia and other psychiatric disorders
  • Explain how to use the available VMAT2 inhibitors to manage TD

Method of Participation

Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a webpage that will allow you to receive your certificate of credit via email or you may print it out at that time.

The online post-test and evaluation can be accessed at https://tinyurl.com/TDPresent17

Inquiries about CME accreditation may be directed to the University of Cincinnati at forneyba@uc.edu or 513-558-3197.

Joint provider statements

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education. The University of Cincinnati is accredited by the ACCME to provide continuing education for physicians.
 
Physician Credit Designation
The University of Cincinnati designates this Live Activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants Credit Designation
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Nurses

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Disclosure Information

As part of their efforts to ensure balance, independence, objectivity, and scientific rigor, the joint providers of this CME/CE activity have required the faculty and all others involved in the development of the content to disclose any relationships they may have with commercial companies that have a product or service relevant to this activity.

Faculty Disclosures

In accordance with Accreditation Council for Continuing Medical Education (ACCME) Essential Areas and Policies, information about the relationships of presenters with commercial interests (if any) will be included in materials distributed at the conference.


Leslie Citrome, MD, MPH, has indicated he is a Consultant for Acadia, Alkermes, Allergan, Intra-Cellular Therapeutics, Janssen, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Pfizer, Shire and Sunovion; is a Speaker for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva and Vanda; has Stocks in Bristol-Myers Squibb, Eli Lilly, J & J, Merck and Pfizer purchased > 10 years ago; and is a Royalty Recipient of Springer Healthcare (book), UpToDate (reviewer), and Wiley (Editor-in-Chief, International Journal of Clinical Practice).

Planning Committee Members
Shirley Jones No Relevant Relationships
Ruth Kollmer No Relevant Relationships
Margaret McLaughlin, PhD No Relevant Relationships
Rick Ricer, MD No Relevant Relationships
Susan P. Tyler No Relevant Relationships

Resolution of Conflicts of Interest

In accordance with the ACCME Standards for Commercial Support of CME, University of Cincinnati will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

Off-Label Disclosure

The faculty have been instructed to identify investigational drugs or devices or discussion of drugs or devices that is outside of labeling currently approved by the US Food and Drug Administration.

Contact Information for Technical Questions

Please technical questions or concerns to Global Academy for Medical Education at 973-290-8225 or email info@globalacademycme.com.

Copyright Statement

Copyright © 2018 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc., and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, University of Cincinnati, Postgraduate Institute for Medicine, and Frontline Medical Communications will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.